PMID- 23178294
OWN - NLM
STAT- MEDLINE
DCOM- 20130312
LR  - 20220331
IS  - 1468-2060 (Electronic)
IS  - 0003-4967 (Linking)
VI  - 72
IP  - 2
DP  - 2013 Feb
TI  - Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising 
      agents in chronic inflammatory diseases: a real issue, a clinical perspective.
PG  - 165-78
LID - 10.1136/annrheumdis-2012-202545 [doi]
AB  - The introduction of biologics, especially tumour necrosis factor (TNF) 
      inhibitors, has revolutionized the management of chronic inflammatory diseases. 
      However, at least one third of patients with these diseases, receiving TNF 
      inhibitors either do not respond to treatment, or lose initial responsiveness. 
      For a significant proportion, improvement of clinical response is achieved after 
      switching to another anti-TNF drug, suggesting a basis for failure unrelated to 
      the therapeutic target itself. A likely explanation for this is immunogenicity, 
      as all biologics are potentially immunogenic, and the resulting anti-drug 
      antibodies (ADAb) can theoretically decrease the efficacy of biologics and/or 
      induce adverse events. Indeed, in these chronic inflammatory diseases, many 
      studies have now established correlations between ADAb formation, low serum drug 
      levels, and the failure or loss of response to anti-TNF antibodies. This article 
      will review key findings related to ADAb, and propose a model wherein monitoring 
      of drug levels and ADAb may be a predictive tool leading to a better choice of 
      biologics. Such an approach could improve chronic inflammatory disease management 
      toward a personalized and more cost-effective approach.
FAU - Vincent, Fabien B
AU  - Vincent FB
AD  - B lymphocyte, BAFF and Autoimmunity Laboratory, Department of Immunology, Monash 
      University, Level 2, AMREP Building, 89 Commercial Road, Melbourne, Victoria 
      3004, Australia. vincent.fabien@gmail.com
FAU - Morand, Eric F
AU  - Morand EF
FAU - Murphy, Kim
AU  - Murphy K
FAU - Mackay, Fabienne
AU  - Mackay F
FAU - Mariette, Xavier
AU  - Mariette X
FAU - Marcelli, Christian
AU  - Marcelli C
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20121124
PL  - England
TA  - Ann Rheum Dis
JT  - Annals of the rheumatic diseases
JID - 0372355
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biological Products)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
CIN - Ann Rheum Dis. 2013 Jul;72(7):e14. PMID: 23585517
MH  - Animals
MH  - Antirheumatic Agents/*immunology
MH  - Biological Products/*immunology
MH  - Humans
MH  - Immune System Diseases/*immunology
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
EDAT- 2012/11/28 06:00
MHDA- 2013/03/13 06:00
CRDT- 2012/11/27 06:00
PHST- 2012/11/27 06:00 [entrez]
PHST- 2012/11/28 06:00 [pubmed]
PHST- 2013/03/13 06:00 [medline]
AID - annrheumdis-2012-202545 [pii]
AID - 10.1136/annrheumdis-2012-202545 [doi]
PST - ppublish
SO  - Ann Rheum Dis. 2013 Feb;72(2):165-78. doi: 10.1136/annrheumdis-2012-202545. Epub 
      2012 Nov 24.